Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03537742 · ClinicalTrials.gov registry record · Phase 2
Cardiac Allograft Vasculopathy Inhibition With Alirocumab
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
NCT03537742: Completed Phase 2 study, sponsored by Stanford University.
NCT03537742 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 114 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03537742, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
Study Summary
The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab when administered early after heart transplantation (HT).The main objective of this project is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when given early after HT.
Interventions
- BIOLOGICAL placebo
- BIOLOGICAL alirocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2019-05-13 |
| Est. Completion | 2025-07-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03537742
The ClinicalTrials.gov registry entry for NCT03537742 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT03537742 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03537742 about?
NCT03537742 is a clinical study titled "Cardiac Allograft Vasculopathy Inhibition With Alirocumab". The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab when administered early after heart transplantation (HT).The main objective of this project is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when given early after HT.
What is the current status of trial NCT03537742?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2019-05-13. Estimated completion is 2025-07-11.
What interventions are being tested in trial NCT03537742?
The interventions under investigation include: placebo (BIOLOGICAL), alirocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03537742?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.